Anti-Glucose Transporter GLUT3 antibody

• Supplier: Abcam
• Catalog: ab53095
• Host: Rabbit
• Clonality: Polyclonal
• Isotype: IgG
• Applications: ICC/IF ICC/IF WB IHC-P ELISA
• Species Reactivities: Rat, Human
• Antigen: Synthetic peptide (Human)
• Description: Rabbit Polyclonal
• Gene: SLC2A3
• Conjugate: Unconjugated

Product images

ab53095 staining Glucose Transporter GLUT3 in human tonsil tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with H2O2 for 10 minutes at 25°C; antigen retrieval was by heat mediation in EDTA pH 8.6 at 100°C for 20 minutes. Samples were incubated with primary antibody (1/200) for 20 minutes at 25°C. An undiluted HRP polymer-conjugated goat anti-rabbit IgG polyclonal was used as the secondary antibody.See Abreview

Human brain tissue labelled with ab53095 at a 1/50 dilution, either incubated with (right image) or without (left image) the peptide.

All lanes : Anti-Glucose Transporter GLUT3 antibody (ab53095) at 1/300 dilutionLane 1 : LOVO cell extractLane 2 : LOVO cell extract with peptide

ICC/IF image of ab53095 stained HepG2 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab53095, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

Product References

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT - Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT

Revheim ME, Kristian A, Malinen E, Bruland OS, Berner JM, Holm R, Joensuu H, Seierstad T. Acta Oncol. 2013 May;52(4):776-82.

Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and - Differential effects of HIF-1 inhibition by YC-1 on the overall outcome and

Yan J, Zhou B, Taheri S, Shi H. PLoS One. 2011;6(11):e27798.